Shares of Amarin Corp AMRN fell 0.2% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 100.00% over the past year to ($0.02), which missed the estimate of $0.01.
Revenue of $156,499,000 up by 39.22% year over year, which beat the estimate of $154,630,000.
Outlook
Amarin Corp hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 05, 2020
Time: 07:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/38230
Recent Stock Performance
Company's 52-week high was at $26.12
Company's 52-week low was at $3.36
Price action over last quarter: down 27.41%
Company Overview
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
